Vivoryon Therapeutics N.V.

A biotech developing a single asset is engaged in a high-risk business, and doubly so when that asset is intended to treat Alzheimer’s disease. Today Vivoryon Therapeutics N.V. lost this gamble, dis

After many attempts and failures to bring a disease-modifying therapy forward for Alzheimer’s disease, the triumph of Eisai Co., Ltd. / Biogen, Inc. ’s amyloid protofibril-clearing antibody lecanemab

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Quadria-Led Consortium Takes Foothold I

With Alzheimer's disease back in the spotlight following Biogen Inc. 's surprise move to file aducanumab for US approval, Germany's Vivoryon Therapeutics has raised €43m to progress its mid-stage ass